The Rising Prevalence Of Myeloproliferative Diseases Driving Market Growth Due to Aging-Related Hematological Abnormalities Is Contributing To Changes In The Polycythemia Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Polycythemia Market Between 2026 And 2030?

The polycythemia market has demonstrated significant expansion over recent years. Its value is anticipated to rise from $4.68 billion in 2025 to $4.99 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.7%. This historical growth can be linked to the increasing occurrence of myeloproliferative disorders, greater public understanding of rare blood diseases, the establishment of more specialty hematology centers, an increase in diagnostic testing, and the expanded use of cytoreductive drugs.

The polycythemia market is anticipated to show significant expansion in the coming years. It is projected to reach $6.53 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth throughout the forecast period stems from progress in targeted JAK2 therapies, the increasing embrace of genetic screening, a surging requirement for personalized treatment strategies, enhanced accessibility to specialty biologics, and an expanding elderly demographic. Prominent trends expected during this period encompass the growing adoption of Janus Kinase inhibitors, the rising application of interferon-based injectable treatments, a heightened inclination towards therapeutic phlebotomy procedures, the broadening scope of hematocrit monitoring diagnostics, and a shift towards combination drug therapy approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33266&type=smp

Which Strong Drivers Are Impacting The Polycythemia Market Growth?

The polycythemia market is anticipated to grow as a result of the increasing occurrence of myeloproliferative diseases. Myeloproliferative diseases represent a collection of uncommon blood conditions characterized by the abnormal overproduction of blood cells in the bone marrow, leading to impaired blood function and circulation. A primary factor contributing to the rising incidence of these disorders is the growing prevalence of age-related hematological abnormalities, as aging populations exhibit greater susceptibility to bone marrow dysfunction. Polycythemia, being a significant subtype of myeloproliferative diseases involving the excessive production of red blood cells, plays a vital role in enhancing clinical understanding, diagnosis, and ongoing monitoring of these conditions, thereby supporting market expansion. For instance, in September 2024, Blood Cancer United, a US-based nonprofit dedicated to curing blood cancers, reported that an estimated 120,000 people in the United States were living with or in remission from myeloproliferative neoplasms (MPNs) in 2023, highlighting an increased prevalence of these chronic hematologic disorders. Consequently, the rising incidence of myeloproliferative diseases is a key driver for the growth of the polycythemia market.

What Segment Categories Shape The Polycythemia Market Segment Landscape?

The polycythemia market covered in this report is segmented –

1) By Type: Primary polycythemia; Secondary polycythemia; Pseudopolycythemia

2) By Drug Class: Antimetabolites; Janus Kinase 2 Inhibitors; Myelosuppressive Agents; Selective Serotonin Reuptake Inhibitors; Folic Acid; Other Drug Classes

3) By Route Of Administration: Oral; Intravenous; Intramuscular

4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Primary Polycythemia: Polycythemia Vera; Familial Primary Polycythemia

2) By Secondary Polycythemia: Hypoxia Induced Polycythemia; Tumor Associated Polycythemia; Drug Induced Polycythemia; Hormone Induced Polycythemia

3) By Pseudopolycythemia: Stress Related Polycythemia; Dehydration Related Polycythemia; Plasma Volume Contraction Related Polycythemia

Which Trends Are Contributing To Changes In The Polycythemia Market?

Major companies operating in the polycythemia market are concentrating on advanced innovations, with rusfertide standing out as a first-in-class hepcidin mimetic peptide. This innovation effectively lessens the requirement for frequent phlebotomies, simultaneously enhancing hematocrit control and the quality of life for patients. A hepcidin mimetic is defined as a drug or compound engineered to mimic hepcidin, which is the body’s chief hormone for regulating iron balance. As an example, in March 2025, Takeda Pharmaceutical Company Limited, a biopharmaceutical company based in Japan, disclosed positive topline findings from its Phase 3 VERIFY study of rusfertide in patients with polycythemia vera. The study results demonstrated a significant decrease in phlebotomy dependence, improved hematocrit control, and valuable patient-reported outcomes, all while sustaining a favorable safety profile.

Who Are The Companies Operating Across The Polycythemia Market Value Chain?

Major companies operating in the polycythemia market are Bristol Myers Squibb Company, Roche Holding AG, Merck And Company Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, Ionis Pharmaceuticals Inc., CTI BioPharma Corp., AOP Orphan Pharmaceuticals AG, Silence Therapeutics Plc, Italfarmaco S.p.A., PharmaEssentia Corporation, Karyopharm Therapeutics Inc., Protagonist Therapeutics Inc., Kartos Therapeutics Inc., Geron Corporation, and Perseus Proteomics Inc.

Get The Full Polycythemia Market Report:

https://www.thebusinessresearchcompany.com/report/polycythemia-market-report

Which Region Leads The Polycythemia Market In Overall Market Size?

North America was the largest region in the polycythemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polycythemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Polycythemia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=33266&type=smp

Browse Through More Reports Similar to the Global Polycythemia Market 2026, By The Business Research Company

Medical Polycarbonate Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-polycarbonate-global-market-report

Hyperlipidemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Polycystic Ovarian Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795